We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+35.53%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.48B
AUM Growth
+$248M
(+20%)
Cap. Flow
-$58.8M
Cap. Flow
% of AUM
-3.97%
Top 10 Holdings %
Top 10 Hldgs %
45.09%
Holding
80
New
10
Increased
13
Reduced
36
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
InflaRx
IFRX
|
+$41.5M |
| 2 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$30.2M |
| 3 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$28.9M |
| 4 |
CRISPR Therapeutics
CRSP
|
+$27.7M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$27M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TSRO
TESARO, Inc.
TSRO
|
+$66.8M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$46M |
| 3 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$37.2M |
| 4 |
Theravance Biopharma
TBPH
|
+$22.6M |
| 5 |
argenx
ARGX
|
+$20.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
InflaRx
IFRX
$243M
| $97.9M | 6.62% |
2,590,000
+1,114,860
| +76% | +$41.5M |
|
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
| $83.8M | 5.66% |
+925,000
| New | +$78.7M |
|
|
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $78.8M | 5.33% |
1,075,000
-676,699
| -39% | -$46M |
|
4
Ascendis Pharma A/S
ASND
$16.5B
| $70.6M | 4.77% |
600,000
+261,544
| +77% | +$22.9M |
|
|
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
| $70.2M | 4.74% |
3,600,000
-902,498
| -20% | -$14.2M |
|
6
AnaptysBio
ANAB
$1.54B
| $67.2M | 4.54% |
920,000
-185,557
| -17% | -$12.8M |
|
|
BHVN
7
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $56.6M | 3.83% |
1,100,000
+450,000
| +69% | +$19.4M |
|
|
RETA
8
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $52.6M | 3.55% |
615,000
-59,251
| -9% | -$4.92M |
|
|
PRNB
9
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $48M | 3.24% |
1,411,898
-62,464
| -4% | -$1.99M |
|
|
QTNT
10
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $41.4M | 2.8% |
115,000
-4,069
| -3% | -$1.43M |
|
|
TCDA
11
DELISTED
Tricida, Inc. Common Stock
TCDA
| $39M | 2.64% |
1,009,586
+277,965
| +38% | +$6.48M |
|
|
BPMC
12
DELISTED
Blueprint Medicines
BPMC
| $36M | 2.43% |
450,000
+88,649
| +25% | +$6.55M |
|
|
13
Sarepta Therapeutics
SRPT
$1.64B
| $35.8M | 2.42% |
300,000
+210,000
| +233% | +$27M |
|
|
CCXI
14
DELISTED
ChemoCentryx, Inc.
CCXI
| $35.1M | 2.37% |
+2,525,900
| New | +$28.9M |
|
|
LKFT
15
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
| $35M | 2.36% |
+300,000
| New | +$30.2M |
|
|
16
argenx
ARGX
$55.2B
| $34.3M | 2.32% |
275,000
-175,000
| -39% | -$20.6M |
|
|
17
CRISPR Therapeutics
CRSP
$4.69B
| $32.1M | 2.17% |
900,000
+800,000
| +800% | +$27.7M |
|
|
MYOK
18
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $31.2M | 2.11% |
600,000
-77,451
| -11% | -$3.57M |
|
|
AXNX
19
DELISTED
Axonics, Inc. Common Stock
AXNX
| $30.5M | 2.06% |
1,272,495
-13,333
| -1% | -$242K |
|
|
ALLK
20
DELISTED
Allakos
ALLK
| $30.4M | 2.05% |
750,000
+600,000
| +400% | +$24.2M |
|
21
Rocket Pharmaceuticals
RCKT
$343M
| $29.8M | 2.02% |
1,700,000
-245,659
| -13% | -$3.88M |
|
|
AUTL
22
Autolus Therapeutics
AUTL
$389M
| $26.8M | 1.81% |
+850,000
| New | +$24.2M |
|
|
ZGNX
23
DELISTED
Zogenix, Inc.
ZGNX
| $24.8M | 1.67% |
450,000
-61,395
| -12% | -$2.92M |
|
24
Kura Oncology
KURA
$793M
| $23.2M | 1.57% |
1,400,000
+850,000
| +155% | +$13.1M |
|
|
KZR
25
DELISTED
Kezar Life Sciences
KZR
| $23.1M | 1.56% |
130,000
-12,291
| -9% | -$2.42M |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
CCA
LBC
C
Cormorant Asset Management's Q1 2019 Portfolio in Review
As of Q1 2019, Cormorant Asset Management held 80 positions worth $1.48B, up 20% from $1.23B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Cormorant Asset Management withdrew a net $58.8M in Q1 2019, closing 16 positions and reducing 36 holdings. Its most notable exit was TESARO, Inc., an estimated $66.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 86% a quarter earlier.
Against the trend, Cormorant Asset Management opened a new position in Lakefront Biotherapeutics American Depositary Shares worth $35M.
- Cormorant Asset Management's largest Q1 2019 buy was Lakefront Biotherapeutics American Depositary Shares: 300,000 shares worth $35M.
- Cormorant Asset Management added most to InflaRx in Q1 2019, an estimated $41.5M increase.
- Cormorant Asset Management's biggest Q1 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $46M.
- Cormorant Asset Management fully exited TESARO, Inc. in Q1 2019, selling an estimated $66.8M.
- Cormorant Asset Management's ten largest holdings make up 45% of its $1.48B portfolio in Q1 2019.
- Cormorant Asset Management opened 10 new positions and closed 16 in Q1 2019.
- Cormorant Asset Management's portfolio value rose 20% quarter-over-quarter to $1.48B.
Based on Cormorant Asset Management's 13F filing for Q1 2019, filed 15 May 2019.